Pancreatic Cancer Drug Gemcitabine Becomes More Effective
According to the National Cancer Institute, 43,140 new cases of pancreatic cancer were reported in the United States in 2010. 36,800 people lost their lives owing to this ailment. The prognosis of this disease is very poor. Less than five percent people survive for five years after the diagnosis. Its complete remission is very rare.
But, according to a research study carried out by the experts from the New University of Georgia, a new protein is identified which can increase the effectiveness of the available drugs for treating this cancer. The results of the study are published in the March 2011 issue of the journal Cancer Research.
The protein identified as CNT1 carried the pancreatic cancer drugs to the tumors. It is found that the efficiency of this protein is reduced in two-thirds of cases.
The researchers genetically over-expressed the CNT1 protein. As a result, the most commonly used pancreatic cancer treatment drug, gemcitabine, was found to be more effective in killing the malignant cells of the pancreas.